1. Introduction {#sec1}
===============

The K--Cl cotransporter (KCC) mediates the coupled movement of K^+^ and Cl^−^ ions across the plasma membrane and is involved in the regulation of cell volume, transepithelial ion transport, and maintenance of intracellular Cl^−^ concentrations (\[Cl^−^\]~i~) \[[@B1], [@B2]\]. Four isoforms of the KCC have been identified and are termed KCC1, KCC2, KCC3, and KCC4 \[[@B3]\]. The four KCC isoforms share a common protein structure with 12 transmembrane regions in a central hydrophobic domain, together with hydrophilic N- and C-termini that may be cytoplasmic \[[@B4]\]. Although the expression of KCC1 is reportedly ubiquitous \[[@B5]\], that of KCC2 is restricted to neurons in the central nervous system \[[@B6]\]. KCC3 is expressed in the muscle, brain, lung, heart, and kidney \[[@B7]\], and KCC4 transcripts are the most abundant in the heart and kidney \[[@B4]\].

Several recent studies described the important roles of KCC in cancer development, tumor invasion, and possibly metastasis \[[@B8]--[@B11]\]. KCC3 was found to be important for cell-cycle progression, migration, and invasion in cervical carcinoma, ovarian cancer, breast cancer, and glioma \[[@B8], [@B9], [@B12], [@B13]\]. In addition, the overexpression of KCC3 downregulated the formation of the E-cadherin/*β*-catenin complex, and the subsequent upregulation of KCl cotransport activity was shown to benefit cancer cells in the epithelial-mesenchymal transition (EMT) \[[@B8]\]. However, the roles of KCC3 in the invasion of esophageal squamous cell carcinoma (ESCC) cells remain uncertain. Furthermore, the clinicopathological meaning of the expression of KCC3 in human ESCCs has not yet been evaluated.

The objectives of the present study were to investigate the roles of KCC3 in the cell migration and invasion of ESCC. Furthermore, we analyzed the expression of KCC3 in human ESCC samples and determined its relationships with the clinicopathological features and prognosis of ESCC patients. Our results revealed the important role of KCC3 in the tumor progression of ESCC.

2. Materials and Methods {#sec2}
========================

2.1. Patients and Primary Tissue Samples {#sec2.1}
----------------------------------------

ESCC tumor samples were obtained from 70 patients with histologically proven primary ESCC who underwent esophagectomy (potentially curative R0 resection) at Kyoto Prefectural University of Medicine (Kyoto, Japan) between 1998 and 2007 and were analyzed retrospectively. These samples were embedded in paraffin 24 h after being fixed in formalin. Patient eligibility criteria included not having developed synchronous tumors or multiple metachronous tumors and not having received preoperative chemotherapy or radiation therapy. We excluded patients with noncuratively resected tumors or nonconsecutive data. All patients gave their written informed consent for inclusion in this study. Relevant clinicopathological and survival data were obtained from the hospital database. Staging was principally based on the seventh TNM staging system \[[@B14]\].

2.2. Immunohistochemistry {#sec2.2}
-------------------------

Paraffin sections (3 *μ*m thick) of tumor tissue were subjected to immunohistochemical staining for KCC3 using the avidin-biotin-peroxidase method. Briefly, paraffin sections were dewaxed in xylene and hydrated through a graded series of alcohols. Antigen retrieval was performed by heating the samples in Dako REAL Target Retrieval Solution (Glostrup, Denmark) for 40 min at 95°C. Endogenous peroxidase activity was quenched by incubating the sections for 30 min in 0.3% H~2~O~2~. Sections were incubated for one hour at room temperature with the following antibody: the KCC3 antibody (HPA034563; Atlas Antibodies AB, Stockholm, Sweden). The avidin-biotin-peroxidase complex system (Vectastain ABC Elite kit; Vector Laboratories, Burlingame, CA, USA) was used for color development with diaminobenzidine tetrahydrochloride. Sections were counterstained with hematoxylin. These sections were then dehydrated through a graded series of alcohols, cleared in xylene, and mounted. Control sections of known positive ESCC were included in each antibody run, and negative control sections were produced by omitting the primary antibody.

Immunohistochemical samples stained with KCC3 were graded semiquantitatively by considering both the staining intensity and percentage of positive tumor cells using an immunoreactive score (IRS) \[[@B15]\]. Staining intensity was scored as 0 (no staining), 1 (weak staining), 2 (moderate staining), or 3 (strong staining). The proportion of positive tumor cells was scored from 0 to 1.0. The score of each sample was calculated as the maximum multiplied product of the intensity and proportion scores (0 to 3.0).

2.3. Cell Culture {#sec2.3}
-----------------

The human ESCC cell lines TE5 and TE9 were obtained from the Cell Resource Center for Biomedical Research at the Institute of Development, Aging, and Cancer (Tohoku University, Sendai, Japan) \[[@B16]\]. These cells were grown in RPMI-1640 medium (Nacalai Tesque, Kyoto, Japan) supplemented with 100 U/mL of penicillin, 100 *μ*g/mL of streptomycin, and 10% fetal bovine serum (FBS). Cells were cultured in flasks or dishes in a humidified incubator at 37°C under 5% CO~2~ in air.

2.4. Small Interfering RNA (siRNA) Transfection {#sec2.4}
-----------------------------------------------

Cells were transfected with 10 nmol/L KCC3 siRNA (Stealth RNAi siRNA \#HSS HSS115159, HSS190762, HSS190763; Invitrogen, Carlsbad, CA) using the Lipofectamine RNAiMAX reagent (Invitrogen), according to the manufacturer\'s instructions. The medium containing siRNA was replaced with fresh medium after 24 h. We used three independent KCC3 siRNAs to exclude off target effects. The control siRNA provided (Stealth RNAi siRNA Negative Control; Invitrogen) was used as a negative control.

2.5. Real-Time Reverse Transcription-Polymerase Chain Reaction (RT-PCR) {#sec2.5}
-----------------------------------------------------------------------

Total RNA was extracted using an RNeasy kit (Qiagen, Valencia, CA). Messenger RNA (mRNA) expression was measured by quantitative real-time PCR (7300 Real-Time PCR System; Applied Biosystems, Foster City, CA) with TaqMan Gene Expression Assays (Applied Biosystems), according to the manufacturer\'s instructions. Expression levels were measured for the following gene: KCC3 (Hs00994548_m1) (Applied Biosystems). Expression was normalized for the KCC3 gene to the housekeeping gene beta-actin (ACTB, Hs01060665_g1; Applied Biosystems). Assays were performed in duplicate.

2.6. Analysis of Cell Migration and Invasion {#sec2.6}
--------------------------------------------

The migration assay was conducted using a Cell Culture Insert with a pore size of 8 *μ*m (BD Biosciences, Bedford, MA). Biocoat Matrigel (BD Biosciences) was used to evaluate cell invasion potential. Briefly, cells (1.5 × 10^5^ cells per well) were seeded in the upper chamber in serum-free medium 24 h after siRNA transfection. The lower chamber contained medium with 10% FBS. The chambers were incubated for 48 h at 37°C in 5% CO~2~, and nonmigrated or noninvaded cells were then removed from the upper side of the membrane by scrubbing with cotton swabs. Migrated or invaded cells were fixed on the membrane and stained with Diff-Quick staining reagents (Sysmex, Kobe, Japan). The migrated or invaded cells on the lower side of the membrane were counted in four independent fields of view at 100x magnification of each insert. Each assay was performed in triplicate.

2.7. Statistical Analysis {#sec2.7}
-------------------------

Statistical analysis was carried out using Fisher\'s exact test to investigate correlations between clinicopathological parameters and KCC3 expression. Survival curves were constructed using the Kaplan-Meier method, and differences in survival were examined using the log-rank test. Multivariate analysis of the factors influencing survival was performed using the Cox proportional hazard model. Multiple comparisons were carried out using Dunnett\'s test after one-way ANOVA. Differences were considered significant when the associated *P* value was less than 0.05. All analyses were performed using statistical software (JMP, version 10; SAS Institute Inc., Cary, NC, USA). Correlation analyses were performed by creating Fit *Y* by *X* plots using JMP.

3. Results {#sec3}
==========

3.1. KCC3 Protein Expression in Human ESCCs {#sec3.1}
-------------------------------------------

An immunohistochemical investigation with the KCC3 antibody revealed the expression of KCC3 in the parabasal cell layer of normal esophageal mucosa ([Figure 1(a)](#fig1){ref-type="fig"}). We examined the expression of KCC3 in 70 primary tumor samples of human ESCC based on their immunohistochemical reactivity. The KCC3 protein was mostly expressed in the cytoplasm of carcinoma cells ([Figure 1(b)](#fig1){ref-type="fig"}). The KCC3 score in the main tumor (MT) varied widely between the tumors. The minimum KCC3 score was 0 while the maximum KCC3 score was 2.4 in MT (median = 0.725; mean ± standard error of the mean (SEM) = 0.780 ± 0.072). Regarding the expression of KCC3 in MT, we divided ESCC patients into 2 groups using the median staining score: a low grade KCC3 expression group with staining scores ≤0.725, *n* = 35, and a high grade KCC3 expression group with staining scores \>0.725, *n* = 35. Figures [1(c)](#fig1){ref-type="fig"} and [1(d)](#fig1){ref-type="fig"} show the representative histopathological findings of low or high KCC3 expression samples. Correlations between the expression of KCC3 in MT and various clinicopathological parameters were analyzed ([Table 1](#tab1){ref-type="table"}). We found correlations between the expression of KCC3 in MT and location of the primary tumor, the pT or pN category ([Table 1](#tab1){ref-type="table"}).

We then focused on the expression of KCC3 in the cancer nest (CN) of ESCC ([Figure 1(e)](#fig1){ref-type="fig"}) and analyzed the KCC3 score in CN. The minimum KCC3 score was 0, and the maximum KCC3 score was 2.6 in CN (median = 1.000; mean ± SEM = 1.087 ± 0.096). The KCC3 score in CN was positively correlated with the KCC3 score in MT (*R* ^2^ = 0.3388, *P* \< 0.0001) ([Figure 2](#fig2){ref-type="fig"}). Regarding the expression of KCC3 in CN, we divided ESCC patients into 2 groups using the median staining score, a low grade KCC3 expression group with staining scores ≤1.000, *n* = 36, and a high grade KCC3 expression group with staining scores \>1.000, *n* = 34, and compared their clinicopathological features ([Table 1](#tab1){ref-type="table"}). A correlation was found between the expression of KCC3 in CN and location of the primary tumor ([Table 2](#tab2){ref-type="table"}). Regarding the comparison of KCC3 scores between MT and CN in each sample, we divided ESCC patients into 2 groups, CN \> MT, *n* = 39, and CN ≤ MT, *n* = 31, and compared their clinicopathological features ([Table 1](#tab1){ref-type="table"}). A correlation was not found between the comparison of KCC3 scores and clinicopathological features ([Table 1](#tab1){ref-type="table"}).

Furthermore, we analyzed the localization of KCC3 expression in tumors. In 48 cases, the expression of KCC3 was found in the invasive front of the tumor ([Figure 1(f)](#fig1){ref-type="fig"}). Regarding the expression of KCC3 in the invasive front of the tumor, we divided ESCC patients into 2 groups, negative (*n* = 22) and positive (*n* = 48), and compared their clinicopathological features ([Table 2](#tab2){ref-type="table"}). A correlation was found between the expression of KCC3 in the invasive front and the MT score, CN score, or their comparison (CN/MT) ([Table 2](#tab2){ref-type="table"}). No correlation was found between the expression of KCC3 in the invasive front and any other clinicopathological parameter ([Table 2](#tab2){ref-type="table"}).

3.2. Prognostic Impact of KCC3 Protein Expression for Patients with ESCC {#sec3.2}
------------------------------------------------------------------------

We determined the prognostic impact of the expression of KCC3 for patients with ESCC. Regarding the expression of KCC3 in MT, no significant difference was observed in the 5-year survival rate between patients with the high grade expression of KCC3 and those with the low grade expression of KCC3 in MT ([Figure 3(a)](#fig3){ref-type="fig"}). Similarly, no significant differences were observed in the 5-year survival rate between patients with the high grade expression of KCC3 and those with the low grade expression of KCC3 in CN ([Figure 3(b)](#fig3){ref-type="fig"}). Regarding comparisons of KCC3 score, the 5-year survival rate of the patients with CN \> MT (55.5%) was lower than that of patients with CN ≤ MT (76.7%) (*P* = 0.133) ([Figure 3(c)](#fig3){ref-type="fig"}). The 5-year survival rate of the patients with KCC3 expression in the invasive front (57.1%) was lower than that of the patients without it (81.8%), although there was no statistical difference (*P* = 0.089) ([Figure 3(d)](#fig3){ref-type="fig"}). Interestingly, when patients were divided into 2 groups, CN \> MT and invasive front positive, *n* = 31, and others, *n* = 39, the 5-year survival rate of patients with CN \> MT and invasive front positive (46.1%) was significantly lower than that of other patients (79.0%) (*P* = 0.022) ([Figure 3(e)](#fig3){ref-type="fig"}).

Furthermore, we assessed which of the 13 variables studied (age, gender, location of the primary tumor, histological type, tumor size, lymphatic invasion, venous invasion, pT and pN category, KCC3 score in MT, KCC3 score in CN and CN/MT, and KCC3 expression in the invasive front) influenced survival following curative resection of esophageal cancer. Univariate analysis of survival after esophagectomy revealed that lymphatic invasion, venous invasion, and the pT and pN categories were found to be significant prognostic factors (*P* = 0.017, 0.017, 0.002, and 0.003, resp.) ([Table 3](#tab3){ref-type="table"}). Multivariate analysis with variables whose *P* values were less than 0.100 in univariate analysis demonstrated that lymphatic invasion, pT and pN category, and KCC3 expression in invasive front were independent prognostic factors (*P* = 0.044, 0.015, 0.011, and 0.001, resp.) ([Table 4](#tab4){ref-type="table"}). KCC3 expression in invasive front was the strongest prognostic factor of all clinicopathological features. These findings suggest that the expression of KCC3 might be a valuable prognostic factor for patients with ESCC.

3.3. KCC3 Controlled Cell Migration and Invasion in ESCC Cells {#sec3.3}
--------------------------------------------------------------

We conducted knockdown experiments with KCC3 siRNA in ESCC cells and analyzed the effects of KCC3 knockdown on cell migration and invasion. We used three independent KCC3 siRNAs to exclude off target effects. All three KCC3 siRNAs effectively reduced KCC3 mRNA levels in both TE5 and TE9 cells ([Figure 4(a)](#fig4){ref-type="fig"}). In TE5 cells, all three KCC3 siRNAs significantly inhibited cell migration and invasion ([Figure 4(b)](#fig4){ref-type="fig"}). In TE9 cell, downregulation of KCC3 inhibited cell migration and invasion, too ([Figure 4(c)](#fig4){ref-type="fig"}). These results suggest that KCC3 plays an important role in regulating cell migration and invasion in ESCC cells.

4. Discussion {#sec4}
=============

Recent studies have shown that ion channels and transporters play crucial roles in cellular functions, and their roles have been studied in cancer cells \[[@B17], [@B18]\]. Various types of ion channels, such as voltage-gated K^+^ channels, voltage-gated HERG channels, Ca~2~ ^+^ channels, and transient receptor potential channels, have been found to be expressed in gastrointestinal cancer cells and tissues and to regulate tumor behavior \[[@B19]--[@B22]\]. Regulators of intracellular pH such as anion exchanger, sodium-hydrogen exchanger, and carbonic anhydrases also related to tumor development of gastrointestinal cancer cells \[[@B23]--[@B25]\]. Furthermore, several reports have indicated that Cl^−^ channels/transporters, such as Cl^−^ channels, chloride intracellular channel (CLIC), KCC, and NKCC, play crucial roles in the tumorigenesis of colorectal, gastric, cervical, breast, lung, and prostate cancer cells \[[@B17], [@B18], [@B26]\]. We have also focused on and investigated transepithelial Cl^−^ transport in various types of cancer cells \[[@B11], [@B27]--[@B29]\].

In the present study, we investigated the KCC3 expression in ESCC and determined its relationships with clinicopathological features and prognosis. To the best of our knowledge, this is the first report examining KCC3 expression in human ESCC tissue. Our results showed that KCC3 expression in MT related to several clinicopathological features, such as the pT and pN categories. However, the expression of KCC3 in MT itself did not have a prognostic impact. Although these results may not be persuasive because of the limitation of a small sample size, they showed that KCC3 was expressed in MT of ESCC from an early stage. Regarding the expression of KCC in cancer tissue, previous studies demonstrated that KCC3 was abundant in cervical carcinoma and CN invaded deeply into stromal tissues whereas KCC4 was abundant in metastatic cervical and ovarian cancer tissues \[[@B8], [@B10]\]. Furthermore, both the progression-free and overall survival rates of patients with the high grade expression of KCC4 were significantly poorer than those of patients with the low grade expression of KCC4 in cervical cancer \[[@B10]\], which suggested a relationship between the expression pattern of KCC and clinical outcome. Therefore, we focused on the distribution of KCC3 in tumors and analyzed its expression in CN or the invasive front of the tumor. Although the expression of KCC3 in CN itself had no prognostic impact, the 5-year survival rate of patients with a CN \> MT score was slightly lower than that of patients with a CN ≤ MT score. Furthermore, the 5-year survival rate of patients in whom KCC3 was expressed in the invasive front was lower than that of patients without it, and multivariate analysis revealed that the expression of KCC3 in the invasive front was the strongest prognostic factor of all clinicopathological features. These results suggest the role of KCC3 in cancer invasion as well as the importance of its distribution in tumors as a prognostic predictor. We have previously identified several prognostic biomarkers in human ESCC, such as Ki-67, antiphosphohistone H3, p21, and E2F5 \[[@B30]--[@B33]\]. The expressions of these cell-cycle related proteins were mainly analyzed in MT. On the other hand, we focused on the distribution of KCC3 in the present study and showed its prognostic impact via cellular invasion.

Recent studies have indicated the importance of KCC in the cell migration and invasion of glioma, cervical, ovarian, and breast cancer cells \[[@B8]--[@B10], [@B12], [@B13]\]. Regarding the mechanism by which KCC regulates tumor invasion, KCC3 was previously shown to downregulate the formation of the E-cadherin/*β*-catenin complex in order to promote EMT, which is important for cervical cancer cell invasiveness \[[@B8]\]. In addition, a previous study reported that the motor protein-dependent membrane trafficking of KCC4 was important for cancer cell invasion \[[@B10]\]. Our*in vitro* study also demonstrated the important roles of KCC3 in cell migration and invasion in ESCC cells. One possible mechanism by which KCC regulates the malignant behavior of cancer cells may be through the regulation of \[Cl^−^\]~i~ \[[@B11], [@B13]\]. Recent studies have shown that \[Cl^−^\]~i~ is a critical signal mediator for the regulation of various cellular functions \[[@B34]--[@B36]\]. For instance, we showed that \[Cl^−^\]~i~ could act as an important signal to control the gene expression of the epithelial Na^+^ channel via a tyrosine kinase in renal epithelial A6 cells \[[@B36]\]. We also previously reported that \[Cl^−^\]~i~ controlled cell-cycle progression in gastric and prostate cancer cells \[[@B27]--[@B29], [@B37], [@B38]\]. Shen et al. showed that an alteration in the \[Cl^−^\]~i~ concentration affected the activity of the retinoblastoma protein and cdc2 kinase, two key cell-cycle regulators that control progression from the G~1~ into the S phase and from the G~2~ into the M phase, respectively \[[@B13]\]. We considered KCC to be one of the important transporters that regulates \[Cl^−^\]~i~ in the steady state and previously showed that the blockage of KCC decreased \[Cl^−^\]~i~ in breast cancer cells \[[@B11]\]. Although this mechanism should be verified in more detail in further studies, these findings suggest that the changes induced in \[Cl^−^\]~i~ by KCC3 may be a critically important messenger that regulates cellular invasiveness in ESCC cells.

In summary, we found that KCC3 played a role in the cell migration and invasion of ESCC cells. An immunohistochemical analysis revealed that the expression of KCC3 in the invasive front of tumors was the strongest prognostic factor in patients with ESCC. A deeper understanding of the role of KCC3 may lead to its use as a crucial biomarker of tumor progression and/or a new therapeutic target for ESCC.
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![KCC3 protein expression in human esophageal squamous cell carcinoma (ESCC). (a) Immunohistochemical staining of noncancerous esophageal epithelia with the KCC3 antibody. Magnification: ×200. (b) Immunohistochemical staining of primary human ESCC samples with the KCC3 antibody. Magnification: ×400. (c) Immunohistochemical staining of primary human ESCC samples with the low grade expression of KCC3 in the main tumor (MT). Magnification: ×200. (d) Immunohistochemical staining of primary human ESCC samples with the high grade expression of KCC3 in the main tumor (MT). Magnification: ×200. (e) Immunohistochemical staining of primary human ESCC samples with the high grade expression of KCC3 in the cancer nest (CN). Magnification: ×200. (f) Immunohistochemical staining of primary human ESCC samples that expressed KCC3 in the invasive front of the tumor. Magnification: ×40.](BMRI2014-936401.001){#fig1}

![A correlation analysis of the relationship between the KCC3 score in main tumor (MT) and KCC3 score in the cancer nest (CN) was performed by producing Fit *Y* by *X* plots. The KCC3 score in CN was positively correlated with the KCC3 score in MT (*R* ^2^ = 0.3388, *P* \< 0.0001).](BMRI2014-936401.002){#fig2}

![Survival curve of patients after curative resection for esophageal squamous cell carcinoma (ESCC) according to the expression of KCC3. (a) Patients were classified into two groups: low grade expression of KCC3 (*n* = 35) and high grade expression of KCC3 (*n* = 35) in the main tumor (MT). (b) Patients were classified into two groups: the low grade expression of KCC3 (*n* = 36) and high grade expression of KCC3 (*n* = 34) in the cancer nest (CN). (c) Patients were classified into two groups based on comparisons of the KCC3 score: CC ≤ MT (*n* = 31) and CN \> MT (*n* = 39) in the cancer nest (CN). (d) Patients were classified into two groups based on the expression of KCC3 in the invasive front of the tumor: negative (*n* = 22) and positive (*n* = 48). (e) Patients were classified into two groups: patients with CN \> MT and invasive front positive (*n* = 31) and others (*n* = 39). ^∗^ *P* \< 0.05: log-rank test.](BMRI2014-936401.003){#fig3}

![KCC3 controlled the cell migration and invasion of esophageal squamous cell carcinoma (ESCC) cells. (a) KCC3 siRNA effectively reduced KCC3 mRNA levels in both TE5 and TE9 cells. Three independent KCC3 siRNAs were investigated to exclude off target effects. (b) The downregulation of KCC3 significantly inhibited cell migration and invasion in TE5 cells. Cell migration and invasion were determined by the Boyden chamber assay. Mean ± SEM; *n* = 3. ^∗^ *P* \< 0.05: Dunnett\'s test (ANOVA: migration; *P* \< 0.0001, invasion; *P* \< 0.0001). (c) The downregulation of KCC3 inhibited cell migration and invasion in TE9 cells. Cell migration and invasion were determined by the Boyden chamber assay. Mean ± SEM; *n* = 3. ^∗^ *P* \< 0.05: Dunnett\'s test (ANOVA: migration; *P* \< 0.0001, invasion; *P* = 0.0210).](BMRI2014-936401.004){#fig4}

###### 

Relationships between the clinicopathological features of esophageal cancer and expression of KCC3 in the main tumor or cancer nest.

  Variable                              MT    *P* value   CN          *P* value   CN/MT   *P* value               
  ------------------------------------- ----- ----------- ----------- ----------- ------- ----------- ----- ----- --------
  Age                                                                                                                
   \<60 years                           11    11          1.000       11          11      1.000       6     16    0.071
   ≥60 years                            24    24          25          23          25      23                      
  Gender                                                                                                             
   Male                                 30    29          1.000       30          29      1.000       25    34    0.520
   Female                               5     6           6           5           6       5                       
  Location of the primary tumor                                                                                      
   Ut-Mt                                18    29          0.0101^∗^   19          28      0.0112^∗^   21    26    1.000
   Lt-Ae                                17    6           17          6           10      13                      
  Histological type                                                                                                  
   Well/moderately differentiated SCC   22    27          0.297       26          23      0.796       22    27    1.000
   Poorly differentiated SCC            13    8           10          11          9       12                      
  Tumor size                                                                                                         
   \<50 mm                              22    27          0.2968      24          25      0.6069      24    25    0.2967
   ≥50 mm                               13    8           12          9           7       14                      
  Lymphatic invasion                                                                                                 
   Negative                             15    18          0.6324      20          13      0.1606      18    15    0.1482
   Positive                             20    17          16          21          13      24                      
  Venous invasion                                                                                                    
   Negative                             19    21          0.8094      20          20      0.8133      18    22    1.000
   Positive                             16    14          16          14          13      17                      
  pT                                                                                                                 
   pT1                                  10    23          0.0037^∗^   14          19      0.2309      18    15    0.1482
   pT2-3                                25    12          22          15          13      24                      
  pN                                                                                                                 
   pN0                                  11    22          0.0160^∗^   15          18      0.473       16    17    0.631
   pN1-3                                24    13          21          16          15      22                      

MT: main tumor; CN: cancer nest; Ut: upper thoracic esophagus; Mt: middle thoracic esophagus; Lt: lower thoracic esophagus; Ae: abdominal esophagus; SCC: squamous cell carcinoma; pT: pathological T stage; pN: pathological N stage.

^∗^ *P* \< 0.05: Fisher\'s exact test.

###### 

Relationships between the clinicopathological features of esophageal cancer and expression of KCC3 in the invasive front of the tumor.

  Variable                              Invasive front   *P* value   
  ------------------------------------- ---------------- ----------- -----------
  Age                                                                 
   \<60 years                           6                16          0.783
   ≥60 years                            16               32          
  Gender                                                              
   Male                                 21               38          0.154
   Female                               1                10          
  Location of the primary tumor                                       
   Ut-Mt                                12               35          0.172
   Lt-Ae                                10               13          
  Histological type                                                   
   Well/moderately differentiated SCC   15               34          1.000
   Poorly differentiated SCC            7                14          
  Tumor size                                                          
   \<50 mm                              14               35          0.575
   ≥50 mm                               8                13          
  Lymphatic invasion                                                  
   Negative                             10               23          1.000
   Positive                             12               25          
  Venous invasion                                                     
   Negative                             13               27          1.000
   Positive                             9                21          
  pT                                                                  
   pT1                                  8                25          0.3035
   pT2-3                                14               23          
  pN                                                                  
   pN0                                  8                25          0.3035
   pN1-3                                14               23          
  MT                                                                  
   Low                                  20               15          \<0.0001∗
   High                                 2                33          
  CN                                                                  
   Low                                  19               17          \<0.0001∗
   High                                 3                31          
  CN/MT                                                               
   CN ≤ MT                              14               17          0.0385∗
   CN \> MT                             8                31          

Ut: upper thoracic esophagus; Mt: middle thoracic esophagus; Lt: lower thoracic esophagus; Ae: abdominal esophagus; SCC: squamous cell carcinoma; pT: pathological T stage; pN: pathological N stage; MT: main tumor; CN: cancer nest.

^∗^ *P* \< 0.05: Fisher\'s exact test.

###### 

Five-year survival rate of patients with esophageal cancer according to various clinicopathological parameters.

  --------------------------------------------------------------------
  Variables                             5-year survival\   *P* value
                                        rate (%)           
  ------------------------------------- ------------------ -----------
  Age                                                       

   \<60 years                           53.13              0.1179

   ≥60 years                            72.2               

  Gender                                                    

   Male                                 65.35              0.8597

   Female                               68.57              

  Location of the primary tumor                             

   Ut-Mt                                73.63              0.0564

   Lt-Ae                                50.82              

  Histological type                                         

   Well/moderately differentiated SCC   71.94              0.2301

   Poorly differentiated SCC            53.43              

  Tumor size                                                

   \<50 mm                              68.68              0.2809

   ≥50 mm                               59.52              

  Lymphatic invasion                                        

   Negative                             78.4               0.0168^∗^

   Positive                             54.78              

  Venous invasion                                           

   Negative                             78.18              0.0169^∗^

   Positive                             48.7               

  pT                                                        

   pT1                                  82.22              0.0024^∗^

   pT2-3                                50.68              

  pN                                                        

   pN0                                  82.72              0.0029^∗^

   pN1-3                                49.68              

  MT                                                        

   Low                                  68.21              0.7838

   High                                 60.56              

  CN                                                        

   Low                                  70.48              0.4151

   High                                 59.25              

  CN/MT                                                     

   CN ≤ MT                              76.74              0.1329

   CN \> MT                             55.48              

  Invasive front                                            

   Negative                             81.82              0.0887

   Positive                             57.07              
  --------------------------------------------------------------------

Ut: upper thoracic esophagus; Mt: middle thoracic esophagus; Lt: lower thoracic esophagus; Ae: abdominal esophagus; SCC: squamous cell carcinoma; pT: pathological T stage; pN: pathological N stage; MT: main tumor; CN: cancer nest.

^∗^ *P* \< 0.05: log-rank test.

###### 

Prognostic factors of esophageal cancer according to multivariate analysis.

  Variables                       Risk ratio   95% CI               *P* value
  ------------------------------- ------------ -------------------- -----------
  Location of the primary tumor                                      
   Ut-Mt                          Ref.         0.861452--2.20629    0.1813
   Lt-Ae                          1.37267                           
  Lymphatic invasion                                                 
   Negative                       Ref.         1.012886--2.725895   0.0437^∗^
   Positive                       1.605417                          
  Venous invasion                                                    
   Negative                       Ref.         0.954510--2.395284   0.08
   Positive                       1.483897                          
  pT                                                                 
   pT1                            Ref.         1.122531--3.250204   0.0146^∗^
   pT2-3                          1.834223                          
  pN                                                                 
   pN0                            Ref.         1.152392--3.450263   0.0110^∗^
   pN1-3                          1.911249                          
  Invasive front                                                     
   Negative                       Ref.         1.357757--4.524146   0.0014^∗^
   Positive                       2.332559                          

Ut: upper thoracic esophagus; Mt: middle thoracic esophagus; Lt: lower thoracic esophagus; Ae: abdominal esophagus; pT: pathological T stage; pN: pathological N stage; Ref.: referent.

^∗^ *P* \< 0.05: Cox\'s proportional hazards model; 95% CI: 95% confidence interval.

[^1]: Academic Editor: Akio Tomoda
